305 related articles for article (PubMed ID: 24435407)
21. Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours.
Durán I; Garzón C; Sánchez A; García-Carbonero I; Pérez-Gracia JL; Seguí-Palmer MÁ; Wei R; Restovic G; Gasquet JA; Gutiérrez L
Clin Transl Oncol; 2014 Mar; 16(3):322-9. PubMed ID: 23943561
[TBL] [Abstract][Full Text] [Related]
22. Opioid Use Among Metastatic Prostate Cancer Patients With Skeletal-related Events.
Yaldo A; Wen L; Ogbonnaya A; Valderrama A; Kish J; Eaddy M; Kreilick C; Tangirala K; Shields K
Clin Ther; 2016 Aug; 38(8):1880-9. PubMed ID: 27478111
[TBL] [Abstract][Full Text] [Related]
23. The cost of treating skeletal-related events in patients with prostate cancer.
Lage MJ; Barber BL; Harrison DJ; Jun S
Am J Manag Care; 2008 May; 14(5):317-22. PubMed ID: 18471035
[TBL] [Abstract][Full Text] [Related]
24. Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.
Carter JA; Joshi AD; Kaura S; Botteman MF
Pharmacoeconomics; 2012 May; 30(5):373-86. PubMed ID: 22500986
[TBL] [Abstract][Full Text] [Related]
25. Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases.
Hagiwara M; Delea TE; Chung K
J Med Econ; 2014 Mar; 17(3):223-30. PubMed ID: 24494707
[TBL] [Abstract][Full Text] [Related]
26. Health resource utilization associated with skeletal-related events: results from a retrospective European study.
Body JJ; Pereira J; Sleeboom H; Maniadakis N; Terpos E; Acklin YP; Finek J; Gunther O; Hechmati G; Mossman T; Costa L; Rogowski W; Nahi H; von Moos R
Eur J Health Econ; 2016 Jul; 17(6):711-21. PubMed ID: 26253584
[TBL] [Abstract][Full Text] [Related]
27. Healthcare resource utilization and associated cost of patients with bone metastases from solid tumors who are naïve to bone-targeting agents: a comparative analysis of patients with and without skeletal-related events.
Hardtstock F; Kocaata Z; Wilke T; Dittmar A; Ghiani M; Belozeroff V; Harrison DJ; Maywald U; Tesch H
Eur J Health Econ; 2021 Mar; 22(2):243-254. PubMed ID: 33459901
[TBL] [Abstract][Full Text] [Related]
28. Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study.
Duran I; Fink MG; Bahl A; Hoefeler H; Mahmood A; Lüftner D; Ghazal H; Wei R; Chung KC; Hechmati G; Green J; Atchison C
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 26865392
[TBL] [Abstract][Full Text] [Related]
29. Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population.
Bhowmik D; Song X; Intorcia M; Gray S; Shi N
Curr Med Res Opin; 2019 Mar; 35(3):513-523. PubMed ID: 30286662
[TBL] [Abstract][Full Text] [Related]
30. Burden of skeletal-related events in prostate cancer: unmet need in pain improvement.
Broder MS; Gutierrez B; Cherepanov D; Linhares Y
Support Care Cancer; 2015 Jan; 23(1):237-47. PubMed ID: 25270847
[TBL] [Abstract][Full Text] [Related]
31. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain.
Pockett RD; Castellano D; McEwan P; Oglesby A; Barber BL; Chung K
Eur J Cancer Care (Engl); 2010 Nov; 19(6):755-60. PubMed ID: 19708928
[TBL] [Abstract][Full Text] [Related]
32. Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Tablazon IL; Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ; Williams SB
Cancer; 2019 Nov; 125(22):4003-4010. PubMed ID: 31390061
[TBL] [Abstract][Full Text] [Related]
33. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.
Delea T; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G
J Support Oncol; 2006; 4(7):341-7. PubMed ID: 16892696
[TBL] [Abstract][Full Text] [Related]
34. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006.
Sathiakumar N; Delzell E; Morrisey MA; Falkson C; Yong M; Chia V; Blackburn J; Arora T; Kilgore ML
Prostate Cancer Prostatic Dis; 2011 Jun; 14(2):177-83. PubMed ID: 21403668
[TBL] [Abstract][Full Text] [Related]
35. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Divers CH; Valderrama A; Freedland SJ
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):380-384. PubMed ID: 27377207
[TBL] [Abstract][Full Text] [Related]
36. Race does not predict skeletal-related events and all-cause mortality in men with castration-resistant prostate cancer.
Patel DN; Howard LE; De Hoedt AM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Klaassen ZW; Terris MK; Freedland SJ
Cancer; 2020 Jul; 126(14):3274-3280. PubMed ID: 32374476
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.
Xie J; Diener M; Sorg R; Wu EQ; Namjoshi M
Clin Breast Cancer; 2012 Aug; 12(4):247-58. PubMed ID: 22694824
[TBL] [Abstract][Full Text] [Related]
38. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.
Davis KL; Mitra D; Kotapati S; Ibrahim R; Wolchok JD
Appl Health Econ Health Policy; 2009; 7(1):31-41. PubMed ID: 19558193
[TBL] [Abstract][Full Text] [Related]
39. Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset.
Kwon DH; Paciorek A; Zhang L; Borno HT; Bucknor M; Small EJ; Aggarwal RR
Urol Oncol; 2022 Aug; 40(8):379.e17-379.e24. PubMed ID: 35750560
[TBL] [Abstract][Full Text] [Related]
40. Healthcare resource utilization and costs in patients with multiple myeloma with and without skeletal-related events.
Ailawadhi S; Medhekar R; Princic N; Fowler R; Tran O; Bhowmik D; Panjabi S
J Oncol Pharm Pract; 2020 Jul; 26(5):1070-1079. PubMed ID: 31631810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
